Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
Rhea-AI Summary
Jaguar Health (NASDAQ:JAGX) said CEO Lisa Conte will present virtually at the Lytham Partners Healthcare Investor Summit on Thursday, January 15, 2026 at 3:30 PM ET. The presentation is virtual and open to registered attendees.
Investors can register via the conference registration link and a replay of the webcast will be available through the same link.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, JAGX gained 10.61%, reflecting a significant positive market reaction. Argus tracked a peak move of +21.4% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $308K to the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While JAGX was down 16.75%, several peers also traded lower: AZTR -8.03%, GRI -10.33%, ONCO -5.73%, QNRX -5.21%, with XRTX +2.5%. The move appears more JAGX-specific than a uniform sector shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | License agreement | Positive | -20.9% | Future Pak license for crofelemer products with up to $38M economics. |
| Jan 06 | Clinical data update | Positive | +9.7% | Proof-of-concept crofelemer data showing parenteral support reductions in IF patients. |
| Jan 02 | FDA grant support | Positive | +7.1% | FDA CVM grant of $240,000 for Canalevia-CA1 effectiveness study in dogs. |
| Dec 15 | Trial abstract | Positive | -11.8% | Abstract submission on preliminary crofelemer data in adult SBS-IF patients. |
| Dec 10 | FDA renewal | Positive | +13.7% | FDA renewal of conditional approval for Canalevia-CA1 through December 2026. |
Recent positive operational and licensing news has produced mixed reactions, with three cases of price gains and two notable sell-offs on otherwise constructive announcements.
Over the past month, Jaguar Health announced multiple clinically and financially meaningful updates. On Dec 10, 2025, the FDA renewed conditional approval for Canalevia‑CA1 through Dec 21, 2026, followed by an abstract submission on SBS‑IF data on Dec 15, 2025. An FDA grant of $240,000 for Canalevia‑CA1 was reported on Jan 1, 2026. On Jan 6, 2026, the company highlighted promising crofelemer data in intestinal failure. Most recently, on Jan 12, 2026, Jaguar signed a U.S. license deal with Future Pak providing up to $38 million in potential value. Today’s conference appearance fits into this ongoing update cadence.
Regulatory & Risk Context
Jaguar Health has an effective S-3 shelf filed on 2025-10-03, effective through 2028-10-03. The company has utilized this shelf at least once, as indicated by a 424B3 prospectus on 2025-11-25 registering shares for resale, which can facilitate future capital-related transactions without a new registration statement.
Market Pulse Summary
The stock surged +10.6% in the session following this news. A strong positive reaction aligns with Jaguar’s recent cadence of operational and financing updates, including the Future Pak license deal and FDA-related milestones. Investors have previously shown both enthusiasm and skepticism, as seen in mixed reactions to positive news. With an effective S-3 shelf filed on 2025-10-03 and prior use via a 424B3, additional capital-related activity could influence how durable any sharp upside move becomes over time.
AI-generated analysis. Not financial advice.
SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit.
Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Healthcare Investor Summit
When: Thursday, January 15, 2026 at 3:30 PM Eastern
Registration link for conference: Click Here
Replay: A replay of the webcast will be available through the same link (Click Here)
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the January 2026 conference listed above. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Jaguar Health (JAGX) presenting at the Lytham Partners Healthcare Investor Summit?
Who from Jaguar Health (JAGX) will present at the January 15, 2026 summit?
How can investors access Jaguar Health's (JAGX) virtual presentation on January 15, 2026?
Will a replay of Jaguar Health's (JAGX) January 15, 2026 presentation be available?
What topics will Jaguar Health (JAGX) cover in the January 15, 2026 presentation?
Is Jaguar Health's (JAGX) January 15, 2026 presentation virtual or in person?
